Xeris Biopharma Holdings, Inc.
XERSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeXeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. Valued at $1.52B, XERS is a small-cap name in its sector. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Market Cap
$1.52B
Beta
0.85
P/E (TTM)
125.71
P/E (Fwd)
22.42
EPS (TTM)
$0.07
EPS (Fwd)
$0.39
ROE
—
ROA
6.3%
Cash
$111.8M
Total Debt
$258.6M
Free CF
$42.2M
52W Change
72.2%
Annual Financials
Cash vs Debt
On the balance sheet, XERS has $111.8M in cash with $258.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $42.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. An ROA of 6.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $110.2M (2022) to $291.8M (2025), reflecting a 165% increase over the period.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing XERS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.